XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc., following a binding letter of intent signed on January 13, 2026. The company has scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million, which, along with the proposed acquisition, is expected to address a deficiency in stockholders' equity under Nasdaq listing requirements. XTL's management cautions that there is no assurance the acquisition will close or that the private placement will be approved in a timely manner, and notes ongoing efforts to regain compliance with Nasdaq rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9645642) on January 29, 2026, and is solely responsible for the information contained therein.